Since inflammatory monocytes depend on the chemokine receptor CCR2 to migrate to foci of inflammation, Leuschner et al. designed 70–80 nm lipid NPs containing siRNA-CCR2 and studied their effect after intravenous administration in mice with different inflammatory conditions (atherosclerosis, myocardial infarction, pancreatic islet transplantation in diabetes, and cancer induced by EL4 lymphoma cell implantation). This evidence concerns the gene CCR2 and diabetes mellitus.